Masimo Corporation (NASDAQ:MASI) Receives Average Recommendation of “Hold” from Brokerages

Shares of Masimo Corporation (NASDAQ:MASI) have been assigned a consensus rating of “Hold” from the eight research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating on the company. The average 1-year price objective among brokers that have covered the stock in the last year is $189.40.

A number of equities analysts have recently weighed in on the company. BTIG Research boosted their price target on Masimo from $198.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Wall Street Zen raised shares of Masimo from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Weiss Ratings restated a “sell (d)” rating on shares of Masimo in a research report on Wednesday, October 8th. Wells Fargo & Company reissued an “overweight” rating and set a $190.00 price target on shares of Masimo in a research note on Friday, December 5th. Finally, Bank of America initiated coverage on Masimo in a research note on Monday, November 17th. They issued a “neutral” rating and a $162.00 target price for the company.

Masimo Stock Down 2.1%

Shares of NASDAQ MASI opened at $134.52 on Wednesday. The firm’s 50-day moving average is $144.78 and its two-hundred day moving average is $151.09. The company has a market capitalization of $7.23 billion, a PE ratio of -12.76, a price-to-earnings-growth ratio of 1.49 and a beta of 1.26. Masimo has a 12-month low of $132.90 and a 12-month high of $194.88. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.84 and a quick ratio of 1.92.

Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Thursday, June 20th. The medical equipment provider reported $1.42 earnings per share for the quarter. Masimo had a negative net margin of 33.20% and a positive return on equity of 33.04%. The business had revenue of $617.00 million during the quarter. Equities analysts anticipate that Masimo will post 4.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Masimo

A number of large investors have recently bought and sold shares of MASI. Twin Tree Management LP acquired a new stake in shares of Masimo during the 1st quarter worth $29,000. MAI Capital Management grew its stake in Masimo by 176.7% during the second quarter. MAI Capital Management now owns 202 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 129 shares during the period. Hilltop National Bank acquired a new stake in Masimo in the 2nd quarter valued at $37,000. Anderson Financial Strategies LLC acquired a new position in shares of Masimo during the first quarter worth about $49,000. Finally, Smartleaf Asset Management LLC raised its stake in shares of Masimo by 80.0% during the third quarter. Smartleaf Asset Management LLC now owns 306 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 136 shares during the period. Hedge funds and other institutional investors own 85.96% of the company’s stock.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.